Educational program by pharmacists to improve diabetes management in patients with Type 1 diabetes
The Impact of Pharmacist Led Education Program on Glycemic Control, Quality of Life and Medication Adherence Among Patients With Type 1 Diabetes Mellitus
This study tests whether an educational program led by pharmacists can help people with Type 1 diabetes in Iraq manage their condition better and improve their quality of life.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | University of Baghdad Academic / other |
| Locations | 1 site (Baghdad) |
| Trial ID | NCT06547970 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of a pharmacist-led educational intervention aimed at improving glycemic control, quality of life, and medication adherence among patients with Type 1 diabetes in Iraq. The intervention focuses on educating patients about their condition, insulin administration techniques, and lifestyle management, including diet and exercise. By providing tailored education, the study seeks to empower patients to better manage their diabetes and improve their overall health outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 16 and older who have been diagnosed with Type 1 diabetes for at least six months and are experiencing uncontrolled hyperglycemia.
Not a fit: Patients with significant comorbid conditions or cognitive impairments that hinder their ability to understand the educational material may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly enhance the quality of life and diabetes management for patients with Type 1 diabetes.
How similar studies have performed: While this specific approach has not been previously studied in Iraq, similar educational interventions in other regions have shown positive outcomes in diabetes management.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \- Patients age ≥ 16 years old who can speak and read the Arabic language. * Had been diagnosed with T1DM for at least 6 months ago. * Had uncontrolled hyperglycemia (glycosylated hemoglobin HbA1C ≥7% and/or fasting blood glucose \>130 mg/dl) * Patients on the same regimen the last 3 months. * patients (or parents) acceptance to participate in the study. Exclusion Criteria: * 1-Patient who have hearing, speech or cognitive deficits that would impair understanding of the questions and receiving the education. 2- Patients with comorbid conditions that may interfere with the study such as asthma, thyroid disorders, adrenal gland disorders, celiac disease, or significant renal impairment. 3-Patients who are taking corticosteroids. 4- Patients who required changing their insulin regimen, increasing the dose \>20% of the previous dose. (21) 5- Patients with conditions that affect red blood cell turnover (hemolytic and other anemias, G-6-PD deficiency, recent blood transfusion, use of drugs that stimulate erythropoiesis, end stage kidney disease and pregnancy. 6-Patients unwilling to participate.
Where this trial is running
Baghdad
- Al-kindy Specialized center for endocrine diseases and diabetes — Baghdad, Iraq (Recruiting)
Study contacts
- Study coordinator: Marwa Al Mukhtar, MSc
- Email: marwa.abd2200m@copharm.uobaghdad.edu.iq
- Phone: 7901735013
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.